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Background: Inflammatory bowel disease (IBD) may result from an aberrant immune 
response to commensal bacteria. Under normal circumstances, the intestinal immune 
system is maintained in a state of controlled inflammation, where balance exists 
between protective immunity mediated by effector cells and tolerance mediated by 
cells with regulatory function. Hence, the inflammation seen in IBD may be caused by 






 regulatory cells (Treg)  and pro-
inflammatory Th17 cells. The aim of this study was to investigate  both Treg and Th17 
cells in the peripheral blood and intestinal mucosa of  the same IBD patients and to 
assess the mucosal cytokine environment. Methods: We recruited 63 IBD patients in 
disease remission and 28 control subjects, and measured Treg and Th17 cells in 
peripheral blood by flow cytometry. The expression of  Th17 promoting cytokines, IL-
1, IL-6, IL-21, IL-23 and TGF- as well as Foxp3 and IL-17a mRNA was analysed 
using real-time RT-PCR in the mucosal biopsies of 24 IBD patients in varying disease 
states and 18 control subjects. Results: A decrease in Treg and increase in Th17 cells 
was observed in the peripheral blood of IBD patients. The elevated expression of 
Foxp3, IL-17a, IL-1 and IL-6 was observed in the mucosa of IBD patients, while 
TGF- was only elevated in ulcerative colitis. Conclusion: IBD is associated with an 
reduced ratio of Treg cells ato Th17 effector cells in peripheral blood and is 
characterised by a pro-inflammatory cytokine microenvironment which supports the 
continued generation of Th17 cells.  
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Crohn’s disease (CD) and ulcerative colitis (UC) are the two main forms of 
inflammatory bowel disease (IBD). The pathogenesis of IBD is thought to originate 
from an aberrant immune response against resident intestinal bacteria resulting in 
chronic inflammation.
1
 The intestinal mucosa is normally maintained in a state of 
controlled inflammation, in which an equilibrium exists between protective immunity 
and tolerance to self antigens or commensal bacteria.
2
 Tolerance is mediated by 
regulatory T cells (Tregs), a sub-population of CD4
+
 T cells that control immune 
responses in the gut by inhibiting the proliferation and effector functions of other T 
cells.
3
 Treg are identified by expression of the high affinity interleukin (IL)-2 receptor 
-chain (CD25),3 however CD25 is also upregulated on the surface of activated CD4+ 
T cells, making this a non exclusive marker.
4
 Treg also express the transcription factor 
Forkhead box p3 (Foxp3), which is crucial for their development and function.
5
 
Although the mechanism through which Treg suppress proliferation of other T cells is 
not clear,
6
  there is evidence that they play an important role in preventing 




There is growing evidence in mouse that Treg and Th17 cells are linked from a 
developmental perspective, where the same naïve T cell precursor pool that generates 
Treg cells is capable of generating IL-17a producing CD4
+
 T helper (Th)17 cells. 
8, 9
 In 
murine models, transforming growth factor (TGF)- drives the differentiation of naïve 
T cells to a Treg phenotype, whereas Th17 cells are induced in the presence of IL-6 and 
TGF-.8, 9 IL-6 and TGF- alone however are not sufficient for the differentiation of 
human Th17 cells.
10
 The potential role of IL-1, IL-6, TGF-, IL-21 and IL-23 in 
promoting human Th17 differentiation has been suggested, although the exact cytokine 
combination requires confirmation.
11-14
 It is suggested that IL-1 and IL-6 or IL-23 can 
induce the production of IL-17 from memory T cells, while IL-21 and TGF- are 
required for the differentiation of Th17 cells from naïve T cells.
14
 Th17 cells express 
the transcription factor retinoic acid-related orphan receptor-t (ROR-t) and pattern 
recognition receptors capable of recognising extracellular bacteria and fungi.
15
 In 
addition to inducing a range of proinflammatory mediators that bridge the innate and 
adaptive immune response, Th17 cells are potent activators of neutrophils to enable 
 4 
clearance of invading pathogens.
16
 Although Th17 cells are believed to play a critical 
biological function in clearing extracellular pathogens,
17
 the inappropriate production 
of IL-17a by these cells is thought to contribute to the pathology of a range of 







 and systemic lupus erythematosus.
22
 IL-17 
expression is upregulated in the intestinal mucosa of IBD patients,
23, 24
 suggesting that 
a Th17 cell driven immune response contributes to the pathology of IBD.
8
 The balance 
between Treg and Th17 cells may be essential for maintaining immune homeostasis, but 
no studies have yet examined this balance in individual IBD patients. 
 
The aim of this study was to determine whether an imbalance of Treg and Th17 effector 
cells is characteristic of patients suffering from IBD.  We developed a stringent Flow 
based staining and gating strategy to accurately enumerate the Treg and Th17 cells 
using Foxp3 and IL17a as the defining markers. We not only investigated each cell 
type independently, but also simultaneously compared the two cells types in the same 
patient subgroup.  We hypothesized that any imbalance seen between these cell types 
may be driven by the cytokine microenvironment of the gut.  We therefore investigated 
the expression of IL-1, IL-6, IL-21, IL-23 and TGF- in the intestinal biopsies of IBD 
and control patients. We found that the numbers of Treg circulating in peripheral blood 
were significantly lower in patients with UC and CD compared to controls, while the 
numbers of Th17 cells were increased in IBD patients.  As we measured both cell types 
in the same patients we are able to report for the first time the ratio of Treg : T 
effectors in these cohorts, revealing a reduced Treg ratio in IBD. In contrast, the 
intestinal mucosa of IBD patients were enriched with both Treg and Th17 marker 




Subjects and Methods 
 
Subjects 
IBD patients were recruited from the Department of Gastroenterology and Hepatology 
at The Queen Elizabeth Hospital (TQEH). Informed consent was obtained from all 
patients before collection of samples.  This study was approved by TQEH Ethics of 
Human Research Committee, and carried out according to the National Statement on 
Ethical Conduct in Research Involving Humans (1999) of the National Health and 
Medical Research Council of Australia and was in accord with the Declaration of 
Helsinki. Thirty-four CD, 29 UC, and 28 control patients were recruited for blood 
collection. All IBD patients were in clinical remission at the time of blood sampling 
based on clinical assessment and blood C-reactive protein levels (CRP<10). Control 
subjects had non-inflammatory disorders (non-ulcer dyspepsia, irritable bowel 
syndrome, reflux) or were healthy volunteers. Intestinal biopsies were obtained from 
an additional subset of IBD patients in various states of disease activity. Biopsies were 
collected from 11 CD, 14 UC and 18 control subjects at colonoscopy. Control subjects 
had non-inflammatory disorders or were undergoing colon cancer screening. Biopsy 
samples were collected and stored in RNAlater (Ambion, Austin, TX) at -20°C to 
prevent RNA degradation prior to extraction.  
 
Analysis by Flow Cytometry 
Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient 
centrifugation on Lymphoprep (Nycomed, Marlow, UK). In order to identify Treg cells, 
1x10
6 
PBMCs were surface labeled with a fluorescein isothiocynate (FITC) labeled 
anti-CD4 (BD, Sydney, NSW, Australia) and phycoerythrin (PE)–Cyanine (Cy)5 
labeled anti-CD25 antibodies (BD, Sydney, NSW, Australia). Surface labeling was 
followed by permeabilisation with the Foxp3 fix/perm solution (eBioscience, San 
Diego, CA) and intracellular labeling with a PE conjugated anti-Foxp3 antibody 
(PCH101, eBioscience, San Diego, CA), according to the eBioscience Foxp3 staining 
protocol. PBMCs (2x10
6
) used for IL-17a assays were stimulated for 5 h using 50 
ng/mL of phorbol myristate acetate (PMA)(Sigma-Aldrich, St. Louis, MO) and 
ionomycin (1 g/mL)(Sigma-Aldrich, St. Louis, MO) in the presence of brefeldin A (5 
g/mL)(Sigma-Aldrich, St. Louis, MO), at 37C and 5% CO2. Cells were washed in 
 6 
PBS and surface labeled with CD3-PE-Cy5, before fixing with 4% w/v 
paraformaldehyde solution and permeabilisation with 0.1% w/v saponin solution. After 
permeabilisation, all wash buffers contained 0.1% w/v saponin. Cells were blocked 
with 5% w/v non-fat dry milk powder solution in PBS/0.1% w/v saponin for 30 min 
then intracellular labeling performed with anti-IL17aPE (clone ebio64DEC17, 
eBioscience, San Diego, CA). Flow cytometry was carried out using a BD FACscan, in 
which 300,000 - 500,000 events were collected and lymphocytes were gated based on 
their forward and side light scatter properties. Data were analyzed with the Cell Quest 
analysis program (BD, Sydney, NSW, Australia). Absolute numbers of Treg cells and 
Th17 cells were calculated as the product of the total lymphocyte count from the 
routine complete blood examination (SA Pathology, South Australia, Australia) and 
target cell frequency of flow cytometric analysis.  
 
Real-time PCR analysis for FOXP3 and IL-17a expression 
Total RNA was isolated from intestinal biopsies using the RNeasy Lipid Minikit 
(Qiagen, Valencia, CA). RNA gel electrophoresis was performed to assess RNA 
quality and samples were accepted if 28S ribosomal RNA bands were present with 
intensity approximately twice that of the 18S RNA band. One microgram of RNA was 
reverse transcribed to obtain complimentary DNA (cDNA) using Qiagen Quantitect 
Reverse transcription kit (Qiagen, Hilden, Germany). Primers were designed to span an 
intron of the genomic sequence. Beta actin forward primer: AAGAGCTACGAG 
CTGCCTGAC; beta actin reverse primer; GTAGTTTCGTGGATGCCACAG 
Foxp3 forward Primer: GAAACAGCACATTCCAGAGTTC, Foxp3 reverse primer: 
ATGGCCCAGCGGATGAG; IL-17a forward primer: CAATCCCACGAAAT 
CCAGGATG, IL-17a reverse primer: GGTGGAGATTCCAAGGTGAGG; IL-6 
forward primer: AAATTCGGTACATCCTCGACGG, IL-6 reverse primer: GGA 
AGGTTCAGGTTGTTTTCTGC; IL-1 forward primer: CAGCTACGAATCTCCG 
ACCAC, IL-1 reverse primer: GGCAGGGAACCAGCATCTTC; IL-21 forward 
primer: CATGGAGAGGATTGTCATCTGTC IL-21 reverse primer: CAGAAATT 
CAGGGACCAA GTCAT; IL-23 forward primer: GGACAACAGTCAGTTCTGCTT, 
IL-23 reverse primer: CACAGGGCTATCAGGGAGC; TGF- forward primer: 




Real time reverse transcription polymerase chain reaction (Real time RT-PCR) was 
carried out using a Corbett Rotorgene RG-3000 (Corbett Research, Sydney Australia), 
with two replicates per sample, a non-template control and non-reverse transcription 
control for each experiment. All reactions were carried out using SYBR green master 
mix (2x) solution (Applied Biosystems, Carlsbad, CA). PCR conditions for gene 
amplification began with a 10 min 95°C enzyme activation step, followed by 40 cycles 
of 95°C for 15 sec and 60°C for 60 sec. Expression of Foxp3, IL-17, IL-1, IL-6, IL-21 
and IL-23 mRNA was normalised to -actin expression. PCR products were purified 
using Qiaquick PCR purification kit (Qiagen, Hilden, Germany), sequenced and 
confirmed against refseqs by BLAST. 
 
Statistical Analysis 
The statistical differences between IBD and the control group were evaluated using the 
two-tailed Mann Whitney ranked sum test. Comparison of paired samples was carried 
out utilizing a paired samples t-test. Data are expressed as mean ± standard error of the 
mean. Statistical significance was achieved when P<0.05. Data were analyzed using 





The average age  SEM of CD, UC and control patients that donated peripheral blood 
were 37.7  2.8, 51.4  4.0 y and 46.8  3.1 y, respectively. Of the total 65 IBD 
patients that donated blood samples, all were in a state of disease inactivity.  Thirty-
five received immunosuppressive treatment (azathioprine, 6-mercatopurine, 
methotrexate), 4 were prescribed corticosteroids, 10 received 5-aminosalicylic acid, 6 
were on a combination of immunosuppressive therapy, corticosteroids and 5-
aminosalicylic acid, and 8 were not taking any medication.  
 
Intestinal biopsy samples were collected from 25 IBD patients, and the average age  
SEM of CD, UC and control patients were 40  12.63 y, 61  15.1 y and 48  14.8 y, 
respectively. Of the total 25 IBD biopsies collected, 6 were from patients with 
moderate disease activity, 8 had mild disease activity and 11 had inactive disease, 
based on global colonoscopic appearance and histologic reports (SA Pathology, 
Adelaide, South Australia). Eleven patients received immunosuppressive therapy, 3 
received corticosteroids, 6 were prescribed a combination of immunosuppressive 









 Treg are decreased in the peripheral blood of IBD subjects 
















T cells also include activated T cells that transiently express Foxp3 and 
are not suppressive.
4
 In order to exclude contaminating CD25
intermediate
 populations, a 
gate for the CD25
bright
 population was set as the top 0.5% of CD4
+
 CD25+ cells, 
capturing the highest expression of CD25 for all patient samples. Representative flow 





 gate with >85% of these cells shown to be Foxp3
+
 in a control patient, while 




 cells in representative IBD patients 






 Treg cells 
among PBMCs ranged from 0.012-0.51% in CD patients, from 0.003-0.47% in UC 
 9 





Treg (mean  SEM per ml of whole blood) in the peripheral blood were 
found to be significantly lower in both CD patients (5.88  0.6 x103/mL, P=0.002) and 




   
Th17 cells are elevated in the peripheral blood of IBD patients 
We measured the numbers of circulating Th17 cells in the peripheral blood by flow 
cytometry to determine if they were increased in IBD patients. In order to identify 
Th17 cells, we utilised their capacity to produce IL-17a upon stimulation.
10
 
Stimulation with PMA and ionomycin to trigger the production of IL-17a was found to 
rapidly downregulate CD4 in some patients, confounding the identification of Th17 
cells (data not shown).  An alternative T lymphocyte marker is CD3, which is also 
expressed by CD8
+
 T cells. Therefore, the ability of CD8
+
 T cells to produce IL-17a 
was evaluated, which revealed that less than 0.03% of CD8
+
 lymphocytes could 





 PBMCs. The proportion of Th17 cells among PBMCs in control subjects 
ranged from 0.10-0.49%, compared with 0.36-1.25% in CD patients and 0.31-1.66% in 
UC patients (Figure 3). Absolute counts of Th17 are given in Figure 4. Th17 cells were 
significantly higher in the blood of CD patients (15.0 ± 2.8 x10
3
/mL, P = 0.0012) and 
UC patients (13.4 ± 2.2 x10
3





An imbalance of Treg and Th17 cells occurs in IBD 
Having shown a decrease in Treg and concomitant increase in Th17 in IBD, this 
relationship was further explored by investigating the balance of Treg and Th17 within 
the same IBD patient and control subjects. To do this the numbers of Treg and Th17 
cells in the peripheral blood of IBD patients were directly compared by simultaneous 
measurement. The balance of Treg and Th17 cells was assessed in 13 control, 15 CD 
and 15 UC patients. While the numbers of Treg and Th17 cells were equivalent in 
controls, the balance of Treg and Th17 cells in the peripheral blood was disrupted in 
IBD patients (Figure 5). The imbalance observed was characterised by a decrease in 
 10 
Treg and an increase in Th17 cells in the peripheral blood of both CD (P < 0.0001) and 
UC (P = 0.004).  
 
Expression of Foxp3 is increased in the intestinal mucosa of IBD patients 
In order to determine if the balance of Treg and Th17 cells was also affected in the 
intestinal mucosa of IBD patients, mucosal biopsy samples were analysed by real time 
RT-PCR. This was done by measurement of the expression of the Treg specific 
transcription factor Foxp3 by real time RT-PCR. A 10-fold increase in Foxp3 
expression was observed in CD patients (P = 0.0007) compared to controls, while a 
100-fold increase in Foxp3 expression was observed in UC patients (P < 
0.0001)(Figure 6a). The expression of Foxp3 in UC patients was highest in those with 
moderate disease activity, lowest in those with mild disease activity and variable in 
those with inactive disease. In contrast, the expression of Foxp3 was comparable 
among CD patients with mild, moderate and inactive disease activity.  
 
Expression of IL-17a is increased in the intestinal mucosa of IBD patients 
In order to determine whether Th17 cell contribute to the maintenance of inflammation 
in the gut, the expression of IL-17a in the intestinal mucosa was measured by real time 
RT-PCR. It was found that a 100-fold increase in IL-17a expression was observed in 
CD patients (P = 0.003) compared to controls, while a 1000-fold increase in IL-17a 
expression was observed in UC patients (P = 0.01) (Figure 6b). Interestingly, UC 
patients with moderate disease activity were found to have the highest expression of 
IL-17a and were the same patients that had the highest expression of Foxp3, while the 
UC patients with mild disease activity that had previously been shown to express the 
lowest amounts of Foxp3 in the intestinal mucosa also expressed the lowest amounts of 
IL-17a. No difference was observed in the expression of IL-17a in CD patients of 
varying disease activities. 
 
Increased expression of IL-1 and IL-6 within the intestinal mucosa of IBD patients 
The cytokine environment within the mucosa of patients with IBD may favour the 
generation of pathological Th17 cells.
25
 The expression of the cytokines IL-1, IL-6, 
IL-21, IL-23 and TGF- within the intestinal mucosa of IBD and control patients was 
investigated. It was found that IL-1 was increased in both CD (P = 0.0032) and UC (P 
 11 
= 0.0005), and IL-6 was expressed at significantly higher levels in the mucosa of CD 
(P = 0.0007) and UC (P = 0.0032) patients (Figure 7a and b). Expression of IL-1 and 
IL-6 in UC patients was highest in those with moderate disease activity, lower in those 
with mild disease activity and variable in those with inactive disease. No correlation 
was seen in CD between disease activity and IL-1 or IL-6 expression. However, we 
found that high levels of IL-17a corresponded with high levels of IL-1 and IL-6 for 
both CD and UC patients. 
 
The expression of TGF- was elevated in UC patients relative to control subjects 
(Figure 7c) (P = 0.048), but was unchanged in CD patients regardless of disease 
activity. Interestingly, a subgroup of UC patients with mild disease activity that had the 
highest expression of TGF- also had low levels of IL-1, IL-6 and IL-17a. However, 
those patients with moderate disease activity and high levels of TGF- had the highest 
expression of IL-1, IL-6 and IL-17. IL-21 was expressed at very low levels in both 
control and IBD patients (data not shown).  There was no significant difference in the 
levels of IL-23 expressed in the intestinal mucosa of both IBD patients and controls 







In this study, we have demonstrated that IBD is characterized by a decrease of Treg and 
an increase in Th17 cells in the peripheral blood of patients in disease remission. In 
varying states of disease activity, an increase in the surrogate markers of Treg and Th17 
cells, namely Foxp3 and IL-17a, was also observed in the intestinal mucosa. Previous 
work has shown increased numbers of Treg in the lamina propria and mesenteric lymph 
nodes of IBD patients.
26-28
 However, our study found that in the intestinal mucosa of 
both CD and UC patients, Foxp3 and IL-17a were both highly expressed, suggesting 
that Treg may be actively recruited into the intestinal mucosa in order to suppress pro-
inflammatory Th17 immune responses. The expression of Foxp3 in the intestinal 
mucosa may alternatively be accounted for by activated T cells transiently expressing 
Foxp3 that do not exhibit suppressive activity,
4
 which are hence unable to suppress the 
Th17 cells. Alternatively, while Treg isolated from the gut associated lymphoid tissue 
and peripheral blood of IBD patients have been demonstrated to be functionally 
suppressive ex vivo,
28,29
 their ability to regulate Th17 proliferation and effector activity 
may be limited in vivo due to a pro-inflammatory cytokine environment.  
 
Recent research has indicated the plasticity of human Treg that express ROR-t and IL-
17 with the loss of suppressive function in the presence of high levels of IL-1 and IL-
6.
30, 31
 Hence, the prolonged exposure of Treg to these inflammatory cytokines may not 
only paralyze their suppressive function, but may culminate in their conversion to 
Th17 cells.
30, 31
 This process may account for the deficit in Treg numbers that we 
observed in the peripheral blood of IBD patients, which was accompanied by an 
increase in the numbers of Th17 cells (Figure 5). The imbalance of Treg and Th17 cells 
circulating in the peripheral blood of IBD patients may account for the relapsing and 
remitting nature of intestinal inflammation, and approaches that aim to re-establish and 
maintain this balance may provide an effective therapeutic strategy.  
 
In mice the differentiation of Th17 cells is induced in the presence of IL-6 and TGF-, 
while TGF- alone induces the generation of Treg.
8
 In contrast, IL-6 and TGF- are not 
sufficient for the generation of Th17 cells in humans.
10
 A range of additional cytokines 
are proposed to induce Th17 differentiation in humans, including combinations of IL-
 13 
1, IL-6, IL-21, IL-23 and TGF-.11-14 While IL-23 is important in the development 
and maintenance of Th17 cells,
32
 and has been found to be elevated in CD but not  
UC,
33
 we found no difference in the expression of IL-23 in the intestinal mucosa of 
control and IBD patients. However, signalling through IL-23 may still play a role in 
disease pathogenesis as genome-wide association studies have identified 
polymorphisms in the IL-23 receptor (IL-23R) in IBD patients, and increased 
expression of IL-23R has previously been shown in both CD and UC.
32, 34
 An 
alternative pathway of Th17 differentiation involves IL-21 in combination with TGF-
14 which may be a mechanism that frustrates the resolution of inflammation 
promoted by TGF-in IBD. However, we were not able to confirm this as the 
expression of IL-21 was low or undetectable in the mucosa of IBD patients and those 
of control patients. Alternative sources of IL17a in the mucosa could include memory 
T cells as induction of IL-17a secretion from these cells by IL-1 and IL-6 has been 
shown.
14
 The expression of TGF- was not elevated in CD patients, suggesting that 
this cytokine does not affect the pro-inflammatory cytokine network associated with 
Th17 cells in the intestinal mucosa. 
 
Both IL-1 and IL-6 were expressed at significantly higher levels in the intestinal 
mucosa of IBD patients (Figure 7). IL-1 and IL-6 expression correlated with disease 
activity in UC, with high expression observed in moderate disease activity and lower 
expression in mild disease activity. Strikingly, the expression of IL-17a correlated 
closely with IL-1 and IL-6 expression in both UC and CD patients, suggesting these 
cytokines are involved in driving Th17 production in IBD patients. This was also true 
for IBD patients with inactive disease, where Th17 cells may accumulate in the 
intestinal mucosa and promote relapse into active disease.  
 
The protective role of TGF-in UC may also be important, as a subset of patients with 
the highest levels of TGF- also showed low IL-17a, IL-1 and IL-6 expression 
(Figures 6 and 7).  Elevated TGF- has been implicated in the differentiation of Treg,
35
 
although these patients concurrently had low Foxp3 expression in the intestinal mucosa 
suggesting low levels of Treg were present.  In patients with moderate disease activity, 
elevated levels of TGF- expression were accompanied by high levels of IL-1, IL-6 
and IL-17. TGF- is a suppressive cytokine with immunoregulatory properties 
 14 
including inhibition of the differentiation of effector cells and the production of pro-
inflammatory cytokines,
36
 hence TGF- may only be protective when in the absence of 
pro-inflammatory cytokines and promote Th17 cells in the presence of IL-1 and IL-6.  
 
In summary, we have shown that IBD is characterised by an imbalance between Th17 
effector cells and Treg cells, with elevated Th17 cells and a cytokine microenvironment  
exists that promotes Th17 development. The observed deficit of Treg in IBD patients 
may impair the ability of the immune system to limit excessive pathogenic Th17 
driven immune responses in the intestinal mucosa. Interestingly, the balance between 
the numbers of Treg and Th17 cells is similarly perturbed in patients with juvenile 
arthritis, primary biliary cirrhosis and coronary heart disease,
37-39
 suggesting that this 
may be a characteristic feature of pathologic inflammatory disorders. Therefore, 
therapeutic approaches that aim to re-establish balance by increasing the number of 
Treg in IBD patients, and specifically targeting Th17 cells, may prove effective in the 
treatment of IBD. Approaches such as these provide more focussed treatment strategies 
for the management of IBD than current broad-spectrum immunosuppressive therapies 
that may leave IBD patients susceptible to cancer or infection. In addition, the 
imbalance demonstrated in the peripheral blood of IBD patients may provide new 
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Figure 1: Detection of human Treg by flow cytometry. PBMC were stained with anti-




gates were set to 
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 and cells within this gate were analyzed for Foxp3. 
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Figure 2: Quantification of Treg in IBD patients. Absolute numbers of Treg cells were 







determined by flow cytometry. Each datum point represents an individual patient 
sample. Median values for each group are represented by the horizontal line. 
 
Figure 3: Detection of human Th17 cells by flow cytometry. PBMC were stained with 















 cells (C).  
 
Figure 4: Quantification of Th17 cells in IBD patients. Absolute numbers of Th17 





 cells determined by flow cytometry. Each datum point represents an individual 
patient sample. The horizontal line represents median values for each group. 
 
Figure 5: The balance of Th17 and regulatory T cell numbers is disrupted in IBD. 






 Treg and Th17 cells were determined 
using the same patient lymphocyte samples. Each datum point represents an individual 
patient sample. The horizontal line represents median values for each group. 
 
Figure 6: RNA was extracted from intestinal biopsies with Foxp3 (A) and IL-17a (B) 
expression quantified by real time RT-PCR and normalized to -actin expression. The 
mucosal disease activity of individual patients is indicated with black circles 
representing patients with inactive disease, black squares representing mild disease 
activity, and white circles indicating patients with moderate disease activity. The 
horizontal line represents the median values for each group.  
 
Figure 7: RNA was extracted from intestinal biopsies and the expression levels of the 
cytokines IL-1 (A), IL-6 (B) and TGF- (C) were determined by real-time RT PCR 
and normalized to -actin expression. The disease activity of individual patients is 
indicated with black circles representing patients with inactive disease, black squares 
representing mild disease activity, and white circles indicating patients with moderate 
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